Skip to content
To the full analysis

Assembly Biosciences stock: balance sheet and debt

ASMB
$20.18Closing price of 12 Nov 2026MEQIRI Score 34 out of 100

Assembly Biosciences has a debt to equity ratio of 0.01.

Daily figure as of 13 Nov 2026

Debt / Equity
0.01
Interest coverage
no data
Current ratio
5.22
Cash & equivalents
$248.11M
Total assets
$257.59M
Equity ratio
80.3%
Goodwill
not reported separately
Net debt
−$245.48M
More cash than debt

Total assets and equity ratio

How large the balance sheet of Assembly Biosciences, Inc. is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2008$870.39Knot reported separatelynot reported separately−1,086.5%$5.77M
2009$166.25Knot reported separatelynot reported separately−8,037.5%$8.93M
2010$14.62Mnot reported separatelynot reported separately79.5%−$12.08M
2011$37.05Mnot reported separatelynot reported separately93.2%−$36.98M
2012$20.56Mnot reported separatelynot reported separately86.6%−$20.49M
2013$27.13Mnot reported separatelynot reported separately90.3%−$27.06M
2014$71.23M$41.74M$12.74M82.2%−$29.09M
2015$133.74M$41.64M$12.64M88.8%−$67.66M
2016$98.12M$41.64M$12.64M81.4%−$52.96M
2017$169.3M$41.64M$12.64M66.8%−$119.95M
2018$268.05M$41.64M$12.64M78.6%−$218.08M
2019$347.89M$41.64M$12.64M78.5%−$261.78M
2020$283.25M$41.64M$12.64M84.9%−$206.28M
2021$191.06Mnot reported separatelynot reported separately88.4%−$140.15M
2022$101.79Mnot reported separatelynot reported separately81.2%−$88.15M
2023$136.82Mnot reported separatelynot reported separately30.0%−$127.91M
2024$119.17Mnot reported separatelynot reported separately28.0%−$108.99M
2025$257.59Mnot reported separatelynot reported separately80.3%−$245.48M

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt.

Equity and debt

What the company owns and owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2008$15.85K−$9.46M$5.79M−0.61
2009$81.29K−$13.36M$9.01M−0.67
2010$14.57M$11.63M$2.49M0.21
2011$36.98M$34.53M$00
2012$20.49M$17.81M$00
2013$27.06M$24.49M$00
2014$29.09M$58.57M$00
2015$67.66M$118.74M$00
2016$52.96M$79.88M$00
2017$119.95M$113.12M$00
2018$218.08M$210.65M$00
2019$274.04M$273.22M$12.27M0.04
2020$216.41M$240.58M$10.13M0.04
2021$146.63M$168.93M$6.48M0.04
2022$91.61M$82.66M$3.47M0.04
2023$130.25M$41.1M$2.34M0.06
2024$112.08M$33.36M$3.09M0.09
2025$248.11M$206.75M$2.63M0.01

Data status and sources

Score
Daily value of 13 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Weak, published since 7 Nov 2026 (in the score history since 31 Dec 2011)
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy